David Corteville
David Corteville has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Garba Rimamskep Shamaki
Tower Health Reading Hospital
2 shared publications - Anderson Anuforo
Division of Cardiovascular Medicine, SUNY Upstate Medical University , Syracuse, NY 13210
1 shared publication - Andre Lamy
Population Health Research Institute, McMaster University, Hamilton, Canada
1 shared publication - Bruce A. Molitoris
Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
1 shared publication - Craig D. Brown
New Brunswick Heart Centre, Saint John, Canada (C.D.B.).
1 shared publication - Cyril David Mazer
St. Michael's Hospital, University of Toronto
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e037951
Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy
Background: Serotonin–norepinephrine reuptake inhibitors (SNRIs) inhibit the presynaptic reuptake of serotonin and norepinephrine and are widely used in the treatment of depression and neuropathic pain. We evaluate the impact of SNRIs use on the clinical outcomes of patients presenting with Takotsubo cardiomyopathy (TCM). Methods: We analyzed data from the TriNetX research network. Patients aged ≥18 years with a principal diagnosis of TCM were identified from January 1, 2003, to December 31, 2023. After excluding patients on SSRIs, stimulants, 5‐fluorouracil, capecitabine, gemcitabine, and trastuzumab, patients with myocarditis, pheochromocytoma, acute myocardial infarction, cocaine‐related disorders, and opioid‐related disorders, were also excluded. The final study population was divided into 2 cohorts: patients on SNRIs and patients not on SNRIs. Propensity score matching was used to adjust for potential confounders. The primary outcome was all‐cause mortality, and the secondary outcome was Takotsubo cardiomyopathy‐related complications. Results: A total of 16 853 patients with a diagnosis of TCM were identified, of which 2482 (14.7%) were on SNRIs. The SNRIs cohort were older (mean age 64.1 versus 63.4 years, P =0.012). After propensity score matching, patients on SNRI had lower 7‐day mortality (odds ratio [OR], 0.59 [95% CI, 0.41–0.84], P =0.004), cardiac arrest (OR, 0.58 [95% CI, 0.40–0.84], P =0.004), and ventricular fibrillation (OR, 0.496 [95% CI, 0.248–0.995], P =0.044). At 1 year, patients on SNRI had lower mortality (OR, 0.80 [95% CI, 0.67–0.96], P =0.015). Conclusions: The use of SNRIs among patients presenting with TCM is associated with lower mortality and lower TCM‐related complications.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e037951
Open AccessSerotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy
Background: Serotonin–norepinephrine reuptake inhibitors (SNRIs) inhibit the presynaptic reuptake of serotonin and norepinephrine and are widely used in the treatment of depression and neuropathic pain. We evaluate the impact of SNRIs use on the clinical outcomes of patients presenting with Takotsubo cardiomyopathy (TCM). Methods: We analyzed data from the TriNetX research network. Patients aged ≥18 years with a principal diagnosis of TCM were identified from January 1, 2003, to December 31, 2023. After excluding patients on SSRIs, stimulants, 5‐fluorouracil, capecitabine, gemcitabine, and trastuzumab, patients with myocarditis, pheochromocytoma, acute myocardial infarction, cocaine‐related disorders, and opioid‐related disorders, were also excluded. The final study population was divided into 2 cohorts: patients on SNRIs and patients not on SNRIs. Propensity score matching was used to adjust for potential confounders. The primary outcome was all‐cause mortality, and the secondary outcome was Takotsubo cardiomyopathy‐related complications. Results: A total of 16 853 patients with a diagnosis of TCM were identified, of which 2482 (14.7%) were on SNRIs. The SNRIs cohort were older (mean age 64.1 versus 63.4 years, P =0.012). After propensity score matching, patients on SNRI had lower 7‐day mortality (odds ratio [OR], 0.59 [95% CI, 0.41–0.84], P =0.004), cardiac arrest (OR, 0.58 [95% CI, 0.40–0.84], P =0.004), and ventricular fibrillation (OR, 0.496 [95% CI, 0.248–0.995], P =0.044). At 1 year, patients on SNRI had lower mortality (OR, 0.80 [95% CI, 0.67–0.96], P =0.015). Conclusions: The use of SNRIs among patients presenting with TCM is associated with lower mortality and lower TCM‐related complications.
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100903
D-48 | The Prevalence and Impact of Body Mass Index on the Outcomes of Patients Undergoing Transcatheter Mitral Valve Repair Using MitraClip: A National Inpatient Sample Analysis 2016 to 2020
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100903
Open AccessD-48 | The Prevalence and Impact of Body Mass Index on the Outcomes of Patients Undergoing Transcatheter Mitral Valve Repair Using MitraClip: A National Inpatient Sample Analysis 2016 to 2020
- Open Access
- 5 October 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (14) , 1133-1144
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study
Background: Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI. Methods: This prospective, multicenter, double-blind, randomized, controlled phase 2 trial evaluated the efficacy and safety of a single 10 mg/kg dose of teprasiran versus placebo (1:1), in reducing the incidence, severity, and duration of AKI after cardiac surgery in high-risk patients. The primary end point was the proportion of patients who developed AKI determined by serum creatinine by postoperative day 5. Other end points included AKI severity and duration using various prespecified criteria. To inform future clinical development, a composite end point of major adverse kidney events at day 90, including death, renal replacement therapy, and ≥25% reduction of estimated glomerular filtration rate was assessed. Both serum creatinine and serum cystatin-C were used for estimated glomerular filtration rate assessments. Results: A total of 360 patients were randomly assigned in 41 centers; 341 dosed patients were 73±7.5 years of age (mean±SD), 72% were men, and median European System for Cardiac Operative Risk Evaluation score was 2.6%. Demographics and surgical parameters were similar between groups. AKI incidence was 37% for teprasiran- versus 50% for placebo-treated patients, a 12.8% absolute risk reduction, P =0.02; odds ratio, 0.58 (95% CI, 0.37–0.92). AKI severity and duration were also improved with teprasiran: 2.5% of teprasiran- versus 6.7% of placebo-treated patients had grade 3 AKI; 7% teprasiran- versus 13% placebo-treated patients had AKI lasting for 5 days. No significant difference was observed for the major adverse kidney events at day 90 composite in the overall population. No safety issues were identified with teprasiran treatment. Conclusions: The incidence, severity, and duration of early AKI in high-risk patients undergoing cardiac surgery were significantly reduced after teprasiran administration. A phase 3 study with a major adverse kidney event at day 90 primary outcome that has recently completed enrollment was designed on the basis of these findings (NCT03510897). Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02610283.
- 5 October 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (14) , 1133-1144
Open AccessTeprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study
Background: Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI. Methods: This prospective, multicenter, double-blind, randomized, controlled phase 2 trial evaluated the efficacy and safety of a single 10 mg/kg dose of teprasiran versus placebo (1:1), in reducing the incidence, severity, and duration of AKI after cardiac surgery in high-risk patients. The primary end point was the proportion of patients who developed AKI determined by serum creatinine by postoperative day 5. Other end points included AKI severity and duration using various prespecified criteria. To inform future clinical development, a composite end point of major adverse kidney events at day 90, including death, renal replacement therapy, and ≥25% reduction of estimated glomerular filtration rate was assessed. Both serum creatinine and serum cystatin-C were used for estimated glomerular filtration rate assessments. Results: A total of 360 patients were randomly assigned in 41 centers; 341 dosed patients were 73±7.5 years of age (mean±SD), 72% were men, and median European System for Cardiac Operative Risk Evaluation score was 2.6%. Demographics and surgical parameters were similar between groups. AKI incidence was 37% for teprasiran- versus 50% for placebo-treated patients, a 12.8% absolute risk reduction, P =0.02; odds ratio, 0.58 (95% CI, 0.37–0.92). AKI severity and duration were also improved with teprasiran: 2.5% of teprasiran- versus 6.7% of placebo-treated patients had grade 3 AKI; 7% teprasiran- versus 13% placebo-treated patients had AKI lasting for 5 days. No significant difference was observed for the major adverse kidney events at day 90 composite in the overall population. No safety issues were identified with teprasiran treatment. Conclusions: The incidence, severity, and duration of early AKI in high-risk patients undergoing cardiac surgery were significantly reduced after teprasiran administration. A phase 3 study with a major adverse kidney event at day 90 primary outcome that has recently completed enrollment was designed on the basis of these findings (NCT03510897). Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02610283.